Inozyme Pharma is a clinical-stage biopharmaceutical company developing novel therapeutics for vasculature, soft tissue, and skeleton diseases. Its lead product candidate, INZ-701, is in Phase 1/2 clinical trials for the treatment of ENPP1 and ABCC6 deficiency and calciphylaxis. The company has a license agreement with Yale University and is headquartered in Boston, Massachusetts.